Maxion Therapeutics, a UK-based biotechnology company, announced on Thursday that it has named Dr Arndt Schottelius as its new chief executive officer, effective 1 March 2024.

Dr Schottelius is to take the firm to its next phase of development. It is part of a planned succession process, with co-founder Dr John McCafferty transitioning from chief executive officer to chief technology officer after having co-founded Maxion. Dr Schottelius has worked as the chief scientific officer at Affimed and served in executive leadership roles as executive vice president of R&D at Kymab, and chief development officer at MorphoSys and senior leadership roles at Genentech. He has 25 years of experience in the pharmaceutical industry. He has experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings and business development.

Eva-Lotta Allan, chair of the board of directors, said, 'It is with great pleasure that I, on behalf of the Board, welcome Arndt to Maxion. As we are expanding our portfolio of KnotBodies and driving our lead programme towards the clinic, his leadership and drug development expertise will be invaluable. I look forward to working with Arndt to shape the vision and drive the company forward.'